[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracardiac-thrombus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracardiac-thrombus":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,59,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":39,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100652013","angiovac-aspiration-therapy-registry-100652013",false,"NCT07769320","AngioVac Aspiration Therapy Registry","A Multicenter, International, Retrospective Observational Study Evaluating the Safety and Effectiveness of the AngioVac System Across Clinical Indications","AVATaR","Inclusion Criteria:\n\n1. Age ≥18 years at time of AngioVac procedure\n2. Patient underwent percutaneous AngioVac aspiration (any AngioVac model or version used clinically during study period)\n3. Procedure performed within study period (January 2018 (or site's institutional start date) - June 2026)\n4. Written informed consent OR documented waiver\u002Fexemption from ethics authority (per local regulations per GDPR)\n\nExclusion Criteria:\n\n1. Insufficient documentation to assess primary safety or effectiveness endpoints (e.g. defined as \\>20% missing data in core endpoint variables)\n2. Patient objection to retrospective data use (where required by local law; GDPR Article 21 opt-out; honored without study impact)\n3. Non-AngioVac procedures: Patients undergoing thrombus\u002Fvegetation removal by surgery or other percutaneous devices only (not AngioVac)","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","As a structured, multinational retrospective registry the AVATAR Registry addresses the following scientific aspects through systematic data collection, centralized quality control, and robust statistical analysis in patients that were treated with the AngioVac Aspiration System:\n\n1. Quantify Real-World Safety: Composite adverse event rates across diverse populations and indications\n2. Assess Effectiveness: Technical and clinical success rates stratified by indication\n3. Identify Predictors: Clinical, procedural, and anatomical factors predicting success versus complications\n4. Generate Publishable Cohorts: Sufficient statistical power (approx. 1000 patients across 8 indication cohorts) for:\n\n   * Indication-specific outcomes\n   * Multivariable prediction models\n   * Time-to-event analyses (30-day and 12-month mortality)\n5. Establish Best Practices: Evidence-based recommendations for patient selection, procedural technique, and follow-up",[25,26,27,28,29,30,31,32,33,34,35,36,37,38],"Intracardiac Thrombus","Intracardiac Mass","Intravascular Thrombosis","Vegetation; Heart","Vegetation; Endocarditis","Vegetation on Catheter","Thrombus of Right Atrium","Thrombus of Right Ventricle","Thrombus Inferior Vena Cava","Thrombus of Pacemaker Electrode","Endocarditis Infective","Endocarditis, Bacterial","Thrombus of Pulmonary Artery","Thrombus on Catheter",[40,41,42,43,44,45],"Percutaneous aspiration","Intracardiac thrombus","Intravascular thrombus","Vegetation","Endocarditis","CIED lead associated vegetation","NOT_YET_RECRUITING","2026-08-12",{"date":49,"type":50},"2026-08-17","ACTUAL",{"date":52,"type":21},"2026-10-01",{"date":54,"type":21},"2027-12-31",{"name":56,"class":57},"Charite University, Berlin, Germany","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":70,"studyType":22,"phases":4,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":58},"100544613","rivaroxaban-for-intracardiac-thrombosis-in-the-pediatric-population-100544613","NCT06371170","Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population","Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population at Different Cardiac Sites","Inclusion Criteria:\n\n* Intracardiac thrombosis demonstration at echocardiography and CMR\u002FCCT confirmation\n* Given informed consent from the parents or tutors\n\nExclusion Criteria:\n\n* \\\u003C 38 weeks of gestational birth\n* \\\u003C 10 days of oral feeding and body weight\n* \\\u003C 2.6 Kg\n* Any major or clinically relevant bleeding event or abnormal coagulation test results within 10 days prior to the enrollment for the whole population","1 Month","16 Years",{"count":69,"type":21},20,"6 Months","The goal of this observational study is to determine the efficacy of rivaroxaban treatment for intracardiac thrombi resolution in pediatric patients (\\\u003C 16 years old) diagnosed with intracardiac thrombosis. The main question it aims to answer is: Does rivaroxaban treatment resolve the thrombosis during a 3-month treatment?\n\nParticipants already taking rivaroxaban as part of their regular medical care for thrombosis resolution. They will undergo monthly visits to check that the treatment is progressing correctly and that no major bleeding has occurred. After 3 months of treatment, they will repeat the radiological imaging investigation to verify the actual resolution of the thrombosis.",[25],"RECRUITING","2024-04-17",{"date":76,"type":50},"2024-04-19",{"date":78,"type":50},"2023-01-01",{"date":80,"type":21},"2027-01-01",{"name":82,"class":57},"Azienda Ospedaliero, Universitaria Ospedali Riuniti",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":58},"100526960","response-of-intracardiac-thrombus-to-anticoagulants-in-patients-with-non-valvular-atrial-fibrillation-lysis-100526960","NCT06141538","Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)","Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS): an Investigator-initiated, National, Multicenter, Retrospective-prospective, Observational Cohort Study","LYSIS","Inclusion Criteria:\n\n* Age ≥18 years old, age ≤80 years old\n* Patients with atrial fibrillation detected by routine surface 12-lead electrocardiography or Holter\n* Transesophageal echocardiography confirmed the presence of cardiac thrombus, and the patient had not received any anticoagulant therapy\n\nExclusion Criteria:\n\n* Echocardiography confirmed valvular heart disease\n* Contraindications to anticoagulants\n* Patients with the previous history of hemorrhagic stroke\n* Low platelet count or functional platelet defects\n* Congenital or acquired coagulation or bleeding disorders\n* Abnormal liver function (liver enzymes \\>2 times the upper limit)\n* Renal failure (endogenous creatinine clearance \\\u003C30ml\u002Fmin)\n* Surgery was planned within the intended study time or had been operated within 30 days before the study\n* Other comorbidities that can cause bleeding, such as tumors\n* Patients with autoimmune diseases or immunodeficiency, or patients who are currently using immunosuppressants and immunomodulators\n* Patients are currently participating in other clinical studies","80 Years",{"count":93,"type":21},500,"This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus. Additionally, the study aims to analyze factors that influence the responsiveness and occurrence of adverse events related to anticoagulant therapy.",[96,25],"Atrial Fibrillation",[96,25,98,99],"Anticoagulation Therapy","Major adverse cardiovascular and cerebrovascular events","2024-04-02",{"date":102,"type":50},"2024-04-04",{"date":104,"type":21},"2024-12-31",{"date":106,"type":21},"2030-12-31",{"name":108,"class":57},"First Affiliated Hospital Xi'an Jiaotong University"]